Avalo Therapeutics (AVTX) Amortization of Deferred Charges (2014 - 2018)
Avalo Therapeutics posted quarterly Amortization of Deferred Charges of -$24342.0 for Q4 2018, down 2434100.0% year-on-year from N/an in Q4 2017, and little changed on a QoQ basis from -$24342.0 in Q3 2018.
Avalo Therapeutics (AVTX) has 5 years of Amortization of Deferred Charges data on file, last reported at -$24342.0 in Q4 2018.
- For the quarter ending Q4 2018, Amortization of Deferred Charges fell 2434100.0% year-over-year to -$24342.0; the trailing twelve-month figure through Sep 2019 stood at -$24342.0 (down 107.44% YoY), and the FY2018 full-year result was $302882.0, up 1387.34% from the prior year.
- Amortization of Deferred Charges for Q4 2018 stood at -$24342.0, roughly flat from -$24342.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $246115.0 in Q2 2018 and bottomed at -$24342.0 in Q3 2018.
- The 5-year median for Amortization of Deferred Charges is $36946.0 (2016), against an average of $48444.5.
- Peak annual rise in Amortization of Deferred Charges reached 2990.73% in 2018, while the deepest fall reached 2434100.0% in 2018.
- A 5-year view of Amortization of Deferred Charges shows it stood at $44292.0 in 2014, then jumped by 100.91% to $88989.0 in 2015, then sank by 68.34% to $28174.0 in 2016, then sank by 100.0% to -$1.0 in 2017, then slumped by 2434100.0% to -$24342.0 in 2018.
- The last three Amortization of Deferred Charges figures came in at -$24342.0 (Q4 2018), -$24342.0 (Q3 2018), and $246115.0 (Q2 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -24,342.00 |
| Dec 31, 2018 | -24,342.00 |
| Sep 30, 2018 | -24,342.00 |
| Sep 30, 2018 | -24,342.00 |
| Jun 30, 2018 | 246,115.00 |
| Jun 30, 2018 | 246,115.00 |
| Mar 31, 2018 | 105,451.00 |
| Mar 31, 2018 | 105,451.00 |
| Dec 31, 2017 | -1.00 |
| Dec 31, 2017 | -1.00 |
| Sep 30, 2017 | -987.00 |
| Sep 30, 2017 | -987.00 |
| Jun 30, 2017 | 7,963.00 |
| Jun 30, 2017 | 7,963.00 |
| Mar 31, 2017 | 13,389.00 |
| Mar 31, 2017 | 13,389.00 |
| Dec 31, 2016 | 28,174.00 |
| Dec 31, 2016 | 28,174.00 |
| Sep 30, 2016 | 36,946.00 |
| Sep 30, 2016 | 36,946.00 |
| Jun 30, 2016 | 45,030.00 |
| Jun 30, 2016 | 45,030.00 |
| Mar 31, 2016 | 52,120.00 |
| Mar 31, 2016 | 52,120.00 |
| Dec 31, 2015 | 88,989.00 |
| Dec 31, 2015 | 88,989.00 |
| Sep 30, 2015 | 112,950.00 |
| Sep 30, 2015 | 112,950.00 |
| Jun 30, 2015 | 22,365.00 |
| Jun 30, 2015 | 22,365.00 |
| Mar 31, 2015 | 69,444.00 |
| Mar 31, 2015 | 69,444.00 |
| Dec 31, 2014 | 44,292.00 |
| Dec 31, 2014 | 44,292.00 |